Is TCRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TCRX. It does not provide personalized investment advice.

TCRX (TScan Therapeutics, Inc. Common Stock) Stock Analysis - Financials

TScan Therapeutics, Inc. Common Stock (TCRX) is a publicly traded Healthcare sector company. As of August 12, 2026, TCRX trades at $0.78 with a market cap of $50.12M and a P/E ratio of -0.80. TCRX moved +0.28% today. Year to date, TCRX is -22.32%; over the trailing twelve months it is -51.75%. Its 52-week range spans $0.72 to $3.43. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces TCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are TCRX's key financials?

TCRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TCRX recently traded at $0.78. Market cap is $50.12M. P/E ratio is -0.80. Revenue is $9.14M.

TCRX Key Metrics

Key financial metrics for TCRX
Metric	Value
Price	$0.78
Market Cap	$50.12M
P/E Ratio	-0.80
EPS	$-0.96
Dividend Yield	0.00%
52-Week High	$3.43
52-Week Low	$0.72
Volume	2.90K
Avg Volume	0
Revenue (TTM)	$9.14M
Net Income	$-124.31M
Gross Margin	0.00%

TCRX Analyst Consensus

5 analysts cover TCRX: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.

Common questions about TCRX

What are TCRX's key financials?: TCRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TCRX recently traded at $0.78. Market cap is $50.12M. P/E ratio is -0.80. Revenue is $9.14M.
Is TCRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TCRX. It does not provide personalized investment advice.